Introduction {#sec1}
============

Urinary tract infections (UTIs) are among the most common bacterial infections in humans ([@bib15]). It is estimated that 40% of women and 12% of men experience a minimum one symptomatic UTI episode during their lifetimes, and 27 to 48% of the affected women suffer from recurrent UTIs ([@bib18]; [@bib56]). UTIs comprise about 40% of all hospital-acquired infections and 50% of bacterial infections that contribute to increased morbidity causing prolonged hospitalization ([@bib9]). UTIs are also an economic problem. In the United States, about 11 million people per year have been treated due to UTIs, generating the cost of about \$6 billion ([@bib53]). Healthcare-associated infections (HAI) are a serious threat for patients in terms of morbidity and mortality, with the healthcare-associated urinary tract infections (HAUTI) being among the most frequent HAI. In Europe, HAUTI account for 19.0% of all HAI ([@bib29]). Community- or healthcare-acquired UTIs are clinically divided into complicated or uncomplicated, and among many other factors, this classification determines what antimicrobial agents can be applied for treatment ([@bib102]). Complicated UTIs require prolonged therapy and occur in patients with renal failure, anatomical urinary tract abnormalities such as urinary obstruction and retention or in patients that use medical devices such as a catheter. Complicated UTIs are also associated with immunosuppression and previous antibiotic exposure. This category of UTIs increases the risk of chronic and/or recurrent infections. Uncomplicated UTIs are found in patients who have no anatomical urinary tract abnormalities and do not use the urinary tract instrumentation. In uncomplicated UTIs, host immune response may successfully fight infection without antibiotic therapy ([@bib53]). The symptomatic UTIs are classified as urosepsis, pyelonephritis (infection of the upper UTI) or cystitis (infection of the lower UTI) ([@bib92]) (Fig. [1](#fig1){ref-type="fig"}). The presence of numerous UPEC cells in the urine (≥ 10^5^ CFU/ml) without the clinical symptoms is called asymptomatic bacteriuria (ABU) and in healthy non-pregnant women is not treated in 20--80% of cases ([@bib82]).

![Classification of urinary tract infections ([@bib12]).](pjm-68-4-403-g001){#fig1}

The increase of antibiotic resistance and appearance of multi-drug resistant (MDR) pathogens in the course of UTI is related to high rates of inadequate antibiotic empirical therapies prescribed without the antibiotic susceptibility testing and finally result in an ineffective UTI treatment ([@bib6]). [@bib98] showed that among 27 542 patients from 856 urology units in 70 countries, 56% of the hospitalized patients were treated with antimicrobials. Among them, 46% received prophylactic antibiotic treatment, 26% of them had the antimicrobials prescribed for the microbiologically proven UTI, 21% − for suspected UTI, and 7% for other infections. The above study also has revealed that broad-spectrum antibiotics were applied such as fluoroquinolones (35%), cephalosporins (27%), and penicillins (16%). The results obtained by [@bib19] showed the correlation between the increased use of broad-spectrum antibiotics and increased antimicrobial resistance and multi-resistance of bacteria. These authors also observed that prophylactic antibiotic treatment of urological patients occurred most frequently in Asia, Africa, and Latin America (86%, 85%, and 84%, respectively), followed by Europe (67%). The increasing number of MDR isolates from UTIs of outpatients makes treatment more difficult. Risk factors of MDR isolated from UTIs include prior use of antimicrobials, hospitalization, genitourinary disturbances, age, and recurrent UTIs ([@bib99]). [@bib91] have recently analyzed the published data (25 studies including 31 284 patients with the confirmed UTI) to determine the risk factors for MDR isolated from UTIs and revealed that previous antibiotic treatment applied from 2 to 365 days earlier was the most commonly identified risk factor. The analysis by [@bib91] showed also that urinary catheterization, previous hospitalization, and residence in a nursing home were strong risk factors of MDR isolated from UTI. Present work aimed to review the available literature published in 2016--2019 to investigate the prevalence of UPEC resistant to antibiotics recommended for the treatment of UTIs. The resistance to antibiotics of UPEC isolated in different regions of the world (European countries, North America, Asia, and some countries of Africa) was compared. The increase of resistance to fluoroquinolones, which was significantly higher in developing countries than in developed countries, has been revealed. Also, the resistance mechanisms identified in these pathogens were discussed.

*Escherichia coli* as a main etiological agent of UTIs {#sec2}
======================================================

The bacteria belonging to the *Enterobacteriaceae* such as *Klebsiella pneumoniae* (about 7%), *Proteus mirabilis* (about 5%), *Citrobacter, Enterobacter*, and other bacteria such as *Pseudomonas aeruginosa, Acinetobacter baumannii, Staphylococcus aureus, Staphylococcus saprophiticus, Enterococcus faecalis, Streptococcus bovis*, and the fungus *Candida albicans* can cause UTIs ([@bib40]; [@bib53]). However, among the bacterial species involved in UTIs, uropathogenic *Escherichia coli* strains (UPEC) are the most common. UPEC account for about 80% of uncomplicated UTIs, 95% of community-acquired infections, and 50% of hospital-acquired infections ([@bib87]). UPEC also remains the most frequent pathogen in complicated UTIs ([@bib12]).

UPEC is a heterogeneous group of extraintestinal pathogenic *E. coli* (ExPEC) that seem to originate from the gut. Many studies suggest that farm animals may be reservoirs of *E. coli* strains carrying virulence genes responsible for UTI in humans. Comparison of the antimicrobial resistance profiles and genetic virulence determinants in the *E. coli* strains isolated from UTI patients, farm animals or meat (particularly chicken) showed high similarity ([@bib43]; [@bib55]). Food-borne urinary tract infections (FUTI) include UTIs acquired from bacteria-contaminated food ([@bib64]). ExPEC can survive in the alimentary tract but do not cause diseases of the digestive system. However, ExPEC strains present in other sites such as central nervous system, blood or the urinary tract may cause serious illness. Four main UPEC phylogroups (A, B1, B2, and D) were identified based on the genomic Pathogenicity Islands (PAI) occurrence and strains belonging to B2 and D groups are isolated most frequently from UTI ([@bib49]; [@bib9]). The intestinal *E. coli* enters the urinary tract system and colonizes the periurethral and vaginal areas and the urethra. After that, bacteria reach the bladder and attach to the surface epithelium using fimbrial and non-fimbrial adhesins ([@bib53]). Adhering bacteria may be internalized into the uroepithelial facet cells, and then they can enter the cytoplasm, replicate and form intracellular bacterial communities (IBCs) being a source of quiescent intracellular reservoirs (QIRs) ([@bib9]). The host immune system may remove some of the IBCs by exfoliation of bladder surface facet cells and excreting them with the urine but the remaining bacteria can grow as a biofilm resistant to immune mechanisms and antibacterial agents ([@bib54]). Some of these bacteria escape from the biofilm, convert to motile form and disseminate into the bladder lumen or even ascend into the kidneys, causing pyelonephritis ([@bib33]). UPEC may also spread from the urinary tract to the bloodstream causing bacteremia. For 15% to 23% of episodes of UTI positive blood cultures could be obtained ([@bib97]; [@bib10]; [@bib95]). The results presented by [@bib4] suggest that treatment failure in UTIs, as well as an inappropriate use and management of urinary catheters in the hospital and community, are important risk factors for the development of *E. coli* bacteremia.

Treatment of UTIs {#sec3}
=================

Based on the general European susceptibility patterns and according to the European Association of Urology guidelines, the following antimicrobial agents are recommended for treatment of uncomplicated cystitis in premenopausal women and uncomplicated pyelonephritis in all European countries: nitrofurantoin, fosfomycin trometamol and trimethoprim-sulfamethoxazole (TMP-SMZ) ([@bib12]). Nitrofurantoin and fosfomycin trometamol are recommended as first-line therapy for uncomplicated cystitis ([@bib17]; [@bib9]). TMP-SMZ is not indicated as the empirical treatment due to the high prevalence of bacterial resistance and can be considered only for the patients with a low prevalence of resistant *E. coli* (\< 20%) ([@bib12]; [@bib17]). Fluoroquinolones (ciprofloxacin and levofloxacin) play an important role in the treatment of more severe infections and septicemia, and thus, ciprofloxacin should be considered as an alternative, not as a first-line antibiotic, in the treatment of uncomplicated cystitis ([@bib12]). Ciprofloxacin could be used as second-line empiric therapy in cases of mild and moderate pyelonephritis or complicated UTI treatment, and as third-line empiric treatment for uncomplicated cystitis. Amoxicillin-clavulanic acid is recommended as first line-therapy for mild and moderate pyelonephritis or complicated UTI, as well as alternative empiric therapy for uncomplicated cystitis. For complicated UTI (high fever, sepsis, vomiting) or severe pyelonephritis, amoxicillin with gentamicin or a second-generation cephalosporin with an aminoglycoside are recommended as first-line empiric therapy, and third-generation cephalosporin applied intravenously as alternative empiric therapy ([@bib17]; [@bib20]). The choice of antimicrobials for the treatment of UTI is also based on local resistance profiles of the pathogen.

Antimicrobial resistance of UPEC {#sec4}
================================

UTIs are associated with significant use of antibiotics that cause implications for bacterial ecology and spread of resistance to antibiotics, especially when it stems from the empirical antimicrobial treatment of recurrent UTIs. Antimicrobial resistance in UPEC and the spreading of MDR UPEC in recent decades is a clinical problem, particularly in women with recurrent UTIs. The increasing frequency of MDR UPEC, especially in developing countries, results in excessive use of broad-spectrum antibiotics such as fluoroquinolones, cephalosporins, and aminoglycosides that raise the cost of treatment and hospitalization ([@bib12]; [@bib79]). Antimicrobial resistance between UPEC is increasing in many countries and shows the time- and area-related variability (Fig. [2](#fig2){ref-type="fig"}).

![The resistance of UPEC to antimicrobials using in the treatment of UTIs.\
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Resistance to nitrofurantoin {#sec5}
============================

According to the European Association of Urology guidelines ([@bib17]), nitrofurantoin is recommended for the treatment of uncomplicated cystitis as first-line empiric therapy. At present, the resistance of UPEC to nitrofurantoin is very low, favoring its use as a first-line antibacterial agent. A retrospective analysis performed by [@bib79] showed that in the United States nitrofurantoin retains a high level of antibiotic activity against urinary *E. coli*. A comparison of the reports from the period of 2003 to 2012 revealed that resistance of *E. coli* isolates from adults to nitrofurantoin only slightly increased (from 0.7% to 0.9%). The rates of UPEC resistance in Germany, Belgium, and Spain in 2013--2014 were below 1.5% ([@bib50]). A slightly higher percentage of UPEC resistant to nitrofurantoin was observed among isolates from elderly hospitalized patients in Argentina (2.3%) ([@bib25]). While in Brazil the rate of UPEC isolates resistant to nitrofurantoin was 6.6% ([@bib23]). In European countries (Romania, Poland, France) the percentage of nitrofurantoin resistant UPEC isolated from outpatients and hospitalized patients ranged from 3% to 3.8% ([@bib21]; [@bib49]; [@bib51]). The study concerning *E. coli* resistance rates at urology clinics in the Netherlands revealed that nitrofurantoin was active against 95% of strains ([@bib94]). Among UPEC from inpatients and outpatients in Bosnia and Herzegovina, 8.23% isolates were resistant to nitrofurantoin ([@bib3]). Lack of susceptibility to nitrofurantoin among *E. coli* isolates from the urine of patients hospitalized in different hospitals in England was low (4.6--6.9%) ([@bib4]). *E. coli* strains isolated from the hospitalized patients with UTIs in Mongolia ([@bib61]), Pakistan ([@bib8]), and Iran ([@bib73]) showed that 5.4%, 6%, and 10% of strains were resistant to this antimicrobial agent, respectively. The study conducted by [@bib72] in India showed that the resistance of UPEC isolated from hospitalized patients to nitrofurantoin was 13.3% and did not significantly change over 5 years (2013--2017). A similar rate of UPEC resistance to nitrofurantoin (12.7%) in Mexico was reported by [@bib74]. These results show that nitrofurantoin remains the drug of choice for the treatment of uncomplicated cystitis, although it should not be used for the treatment of pyelonephritis since its concentration in the renal parenchyma is too low. Additional characteristics, as high efficiency, cost-effectiveness, and weak adverse environmental impact suggest that nitrofurantoin should be the first-choice treatment in uncomplicated UTI in women.

Resistance to fosfomycin {#sec6}
========================

Fosfomycin is an "old" antibiotic used for the treatment of drug-resistant bacterial infections. Fosfomycin shows activity against several *Enterobacteriaceae* species, including those expressing extended-spectrum β-lactamases (ESBL) and metallo-β-lactamases (MBL). Fosfomycin is currently approved for use in some European countries as a single 3 g dose for treating uncomplicated UTIs caused by *E. coli* in women ([@bib26]). The results of [@bib38] showed that all *E. coli* strains investigated were susceptible to fosfomycin. The comparative study on UPEC susceptibility to fosfomycin conducted in Germany, Belgium, and Spain, showed that only \< 1.5% of isolates were resistant to this antibiotic ([@bib50]). In UTI caused by non-resistant uropathogens, clinical cure rates ranged from 87% to 93%, while microbiological cure rates ranged from 80% to 83%. The treatments of UTIs caused by MDR uropathogens with fosfomycin demonstrated an overall microbiological cure rate of 59% ([@bib63]). Antibacterial efficacy of fosfomycin is weaker compared to other first-line agents used in the treatment of uncomplicated UTIs, and thus this drug should be avoided if there is a suspicion of early pyelonephritis.

Resistance to trimethoprim-sulfamethoxazole {#sec7}
===========================================

TMP-SMZ is another important and widely used first-line antimicrobial in the treatment of uncomplicated cystitis. The comparative study performed in the USA by [@bib100] showed that frequencies of TMP-SMZ resistance in UPEC isolates obtained from outpatients with UTI symptoms in 1999--2000 and in 2016--2017 did not significantly change (resistance slightly increased from 16.9% to 17.1%). However, increasing resistance to this drug has recently been was observed in many countries. A majority of studies show resistance at or above the accepted level of 20%, and thus TMP-SMZ should not be used in empiric treatment ([@bib12]). High resistance rate to TMP-SMZ (24.5%) among *E. coli* isolated from urine in 2012--2015 was reported in Switzerland by [@bib28]. The considerable geographic and age-related differences in resistance of UPEC to TMP-SMZ were observed, and the highest resistance was noted in certain regions of Europe in young women. Studies of TMP-SMZ activity against UPEC revealed resistance in European countries (Belgium, Germany, Poland, Switzerland, France, Spain, Bosnia and Herzegovina, and Romania) between 14.6% and 60% ([@bib3]; [@bib49]; [@bib50]; [@bib51]; [@bib21]; [@bib28]; [@bib39]). The TMP-SXT resistance rate in India in 2013 was 52%, and in 2017 it increased up to 59.6% ([@bib72]). A similar rate of resistance of UPEC isolates against TMP-SXT (50.6%) was observed in Brazil ([@bib23]). The activity of TMP-SMZ against UPEC in other regions of the world was significantly lower as the frequencies of TMP-SMZ resistant UPEC isolates ranged from 72.7% in Mexico to 82% in Pakistan ([@bib8]; [@bib74]). High resistance to TMP-SMZ was also observed in Iran (54%), Ethiopia (68.5%), Mongolia (70.9%), and Jordan (73,1%) (Raeispour and Ranjbar 2016; [@bib61]; [@bib75]; [@bib84]). These results indicate that in many countries TMP-SMZ should not be used in empiric UTI therapy due to the high frequency of UPEC resistant to this antimicrobial.

Resistance to fluoroquinolones {#sec8}
==============================

Fluoroquinolones (FQs) are recommended for empirical oral antimicrobial therapy in uncomplicated pyelonephritis ([@bib17]) and they are frequently used for the treatment of UTIs ([@bib27]; [@bib101]; [@bib99]). The increasing emergence of *E. coli* resistant to FQs was reported worldwide, and it has emerged probably due to the excessive use of these antibiotics. The resistance of UPEC to FQs was reported from different countries and the level of resistance is significant. The results of [@bib72] revealed a -high rate of fluoroquinolone resistance in UPEC in India (\> 60%). The results of the meta-analysis on resistance to ciprofloxacin in the community- and hospital-acquired UTIs showed that UPEC resistance to ciprofloxacin was higher in the hospital when compared to the community setting ([@bib31]). In Europe, resistance to FQs was reported in 22% of strains, and the prevalence of fluoroquinolone-resistant UPEC strains was about 31% among hospitalized patients in the United States ([@bib9]). In many parts of the world, \> 20% of *E. coli* isolated from patients with community-acquired uncomplicated UTI and \> 50% of *E. coli* isolated from complicated UTI showed resistance to FQs ([@bib88]). In Poland, resistance to FQs was observed in about 30% of UPEC ([@bib57]). MDR UPEC demonstrated much higher rates of resistance to FQs, ranging from 49% to 72% ([@bib99]). Among FQs, ciprofloxacin is the most commonly prescribed for UTIs because it is available in oral and intravenous preparations. In the group of UPEC strains isolated in 2013--2014 from outpatients in Brasilia, 18.8% were resistant to ciprofloxacin, and resistance to ciprofloxacin was associated with multidrug resistance ([@bib58]). In the United States in the period from 2013 to 2014, 12.1% of *E. coli* isolates from patients with acute uncomplicated and complicated pyelonephritis were resistant to this antibiotic ([@bib88]). A similar percentage of UPEC resistant to ciprofloxacin was noted in other research conducted in the United States in 2016--2017 for isolates from the urine samples from outpatients with symptoms of UTI ([@bib100]). While a higher rate of resistance to ciprofloxacin was detected in UPEC from elderly hospitalized patients in Argentina (42.8%) ([@bib25]), and in UPEC isolates from the community and hospital-acquired infections in Mexico (47.3%) ([@bib74]). [@bib16] found that in Switzerland, over 10 years (1997--2007), resistance to ciprofloxacin increased significantly from 1.8% to 15.9%, which coincided with an increase in ciprofloxacin use in this country. In 2000 in Switzerland FQs were prescribed for treatment of uncomplicated UTIs in 64% of cases. In the recent study conducted in Switzerland in 2012--2015, an increase of resistance to ciprofloxacin from 15.9% ([@bib16]) to 17.4% ([@bib28]) was reported. Although total antibiotic usage in Switzerland is lower than in other European countries, the fluoroquinolone consumption in this country for treatments of urological outpatients comprises 20.1% of all antibiotics ([@bib37]) and it is rather high when compared to an average of 7.3% in other European countries (Filippini et al. 2004), which may explain the increasing fluoroquinolone resistance in UPEC isolates. In 2013--2014 in Belgium, Germany, and Spain the percentage of ciprofloxacin-resistant UPEC strains was 12.9, 17.3, and 39.8%, respectively ([@bib50]). The research conducted in England showed that among *E. coli* isolates from the urine samples from patients, who later developed bacteremia, 20.4% and 15.5% of isolates were resistant to ciprofloxacin in the year and four weeks before the bacteremia onsets. ([@bib4]). Resistance to ciprofloxacin was significantly higher in developing countries (Ethiopia -- 85.5%, Nepal -- 64.6%, Pakistan -- 60.8%, Mongolia -- 58.1%, Jordan -- 55.5%) ([@bib8], [@bib46]; [@bib61]; [@bib75]; [@bib84]) than in developed countries (USA -- 5.1%, Germany -- 10.5%, Switzerland -- 17.4%, France -- 24.8%) ([@bib51]; [@bib28]; [@bib39]; [@bib100]). The study conducted in Switzerland showed also that patient age over 65 years was associated with higher *E. coli* resistance to ciprofloxacin ([@bib28]). According to many authors, the widespread use of fluoroquinolones in the outpatients is the cause of the continuous increase in resistance to this drug. Therefore, ciprofloxacin should be avoided in first-line treatment of UTIs and be used only in more severe infections or as an alternative when the recommended agents cannot be used. Restrictions of ciprofloxacin usage should be enhanced especially in developing countries, where no regulations concerning the use of this antibiotic currently apply ([@bib9]).

Resistance to amoxicillin-clavulanic acid {#sec9}
=========================================

Amoxicillin-clavulanic acid was recommended as first-line therapy for mild and moderate pyelonephritis or complicated UTI or as an alternative empiric therapy for uncomplicated cystitis ([@bib20]). Resistance rates for amoxicillin-clavulanic acid vary regionally. In the United States in 2012, the prevalence of UPEC isolates resistant to this antibiotic in the age groups: below 17, 18--64, and over 65 years were 3.1%, 3.9%, and 5.5%, respectively ([@bib79]). [@bib59] studied *E. coli* urinary isolates collected in the period from 2009 to 2013 from inpatients and outpatients in the Veterans Affairs Care System in the United States and showed that rates of resistance to amoxicillin or ampicillin/beta-lactamase inhibitors were approximately 40%. [@bib74] have recently found that 23.6% of UPEC isolates were resistant to amoxicillin-clavulanic acid in Mexico. The resistance rate to amoxicillin-clavulanic acid among *E. coli* isolates from the urine samples taken from patients of tertiary care hospital in Germany in 2015--2017 was 5.3% ([@bib39]). Between 2015 and 2017 in Romania, ([@bib21]), and in Bosnia and Herzegovina in 2016, 29.0% and 19.6% of UPEC isolates collected from outpatients were resistant to amoxicillin-clavulanic acid ([@bib3]. In Poland in women with uncomplicated UTIs 3.3% of UPEC were resistant to amoxicillin-clavulanic acid in 2003--2006 (Naber et al. 2008). In 2007--2008 the percentage of amoxicillin-clavulanic acid-resistant UPEC isolated from hospital-acquired UTIs in Poland was 13.9% ([@bib49]). In the group of UPEC isolates obtained in 2009--2010 in the urology units in France, 37.6% were resistant to this antimicrobial ([@bib51]) Among UPEC isolated in Argentina from patients over 70 years old with UTIs, without urinary catheters and antimicrobial therapy, 28.6% were resistant to this antibacterial agent ([@bib25]). In England, 30% of *E. coli* isolates from the urine samples from hospitalized patients showed resistance to amoxicillin-clavulanic acid ([@bib4]). High level of resistance to this antimicrobial was reported for UPEC isolates from children hospitalized in 2015--2016 in Nepal (48%) ([@bib68]), and in Pakistan in the group of UPEC isolated from outpatients (71%) ([@bib8]). While very high resistance to amoxicillin-clavulanic acid (83%) was showed for UPEC isolates from hospitalized patients in Jordan ([@bib84]). These results demonstrate that the levels of UPEC resistance to amoxicillin-clavulanic acid varied between geographical regions or patient populations. For this reason, the empiric regimens for uncomplicated and complicated UTIs should be guided by the local susceptibility of *E. coli*. However, definitive regimens should be developed according to the susceptibility results of UPEC, when available.

Resistance to other antibiotics {#sec10}
===============================

Some UPEC isolates can be resistant to ampicillin and first-generation oral cephalosporins ([@bib60]). The resistance to cefuroxime (second-generation cephalosporin) in Belgium, Germany, and Spain was 5.5%, 12.8%, and 16.6%, respectively ([@bib50]). *E. coli* isolates from the urine samples from hospitalized patients in England were found to be resistant (13.8--21.3%) to third-generation cephalosporins (cefotaxime/ceftazidime) ([@bib4]). The percentage of UPEC susceptible to third generation cephalosporins in Romania was 87% ([@bib21]). While, the other research conducted in this country demonstrated that the resistance rate was 47.52% for ampicillin, and 41.16% for tetracycline ([@bib22]). The resistance of *E. coli* isolates from the urinary tract isolated in the urology department in France to amoxicillin, ticarcillin, nalidixic acid was high and reached 61.4%, 59%, and 31.9%, respectively ([@bib51]). In Iran, the resistance to ampicillin, ceftazidime and nalidixic acid was higher than 50%, while amikacin and gentamicin showed high activity against UPEC (89.1% and 82.4% of sensitive isolates, respectively) ([@bib30]). The resistance against gentamicin and amikacin of UPEC isolated from outpatients in Pakistan was 29%, and 4%, respectively ([@bib8]). In Mexico, the resistance rates to antibiotics belonging to aminoglycosides were 28.2%, 19.1%, 10%, and 5.5% for gentamycin, tobramycin, amikacin, and netilmicin, respectively ([@bib74]). The carbapenems, piperacillin-tazobactam, and amikacin were highly active (\> 95% susceptibility) against *E. coli* isolates from UTIs collected from 2010 to 2014 in Canada and the United States ([@bib52]). Carbapenems (ertapenem, imipenem, meropenem, doripenem) are recommended for the treatment of acute uncomplicated pyelonephritis, complicated UTI, and urosepsis ([@bib17]). [@bib83] showed that all UPEC isolates from patients with UTI in Teheran were negative for carbapenemases. Another study on UPEC isolates from Iran confirmed a lack of resistance to meropenem in isolates from outpatients and inpatients ([@bib30]). [@bib8] described a high activity of meropenem in Pakistan since only 1.3% of UPEC were resistant to this antibiotic. However, a recent study from Saudi Arabia about the presence of carbapenem-resistant uropathogenic *E. coli* clones in community-acquired UTIs reported the occurrence of carbapenemases NDM-1 and 5 (the New Delhi metallo-lactamase), and carbapenemases of the OXA-181 type in these strains (Abd El [@bib1]). The emergence of carbapenem-resistant uropathogenic *E. coli* isolates makes treatment of these infections increasingly challenging.

Mechanisms of UPEC resistance to antibiotics {#sec11}
============================================

Resistance to β-lactams is related to the production of different types of β-lactamase enzymes. Among the genes often located on plasmids are those coding multiple types of β-lactamases (*bla* genes) ([@bib6]). β-lactamases hydrolyze the amide bond of the four- membered β-lactam ring of β-lactam antibiotics (penicillin, cephalosporin, monobactams, and carbapenems) ([@bib65]). ESBL are enzymes that confer resistance to β-lactam antibiotics (all penicillins, cephalosporins, and monobactams), except for carbapenems, cephamycins, and β-lactamase inhibitors ([@bib13]). ESBL are the predominant source of *Enterocacteriaceae* resistance to 3rd- and 4th-generation cephalosporins and they developed as a result of mutations in the genes coding for ancestral enzymes blaTEM-1, blaTEM-2, and blaSHV-1 ([@bib24]). Three classes of β-lactamases including TEM and SHV, and since 2000 a new group of ESBL, CTX-M (cefotaximases), were observed among ESBL produced by UPEC ([@bib66]; [@bib83]). Genetic analyses of UPEC from hospitalized patients in different hospital wards in Lodz (Poland) revealed that TEM-1 was present in almost all investigated strains ([@bib6]). Among UPEC isolated from 2013 to 2015 from patients hospitalized in a Department of Internal Medicine and Nephrology in southern Poland, 8% of the strains produced ESBL ([@bib57]). In France, 7.6% of UPEC produce ESBL with the predominance of CTX-M ([@bib51]). The CTX-M enzymes are active against cefotaxime and ceftriaxone and less active against ceftazidime ([@bib14]). UPEC producing ESBL are particularly often detected in developing countries (Iran -- 37.1%, Nepal -- 38.9%, Pakistan -- 40%, and Jordan -- about 50%) ([@bib8]; [@bib68]; [@bib84]). [@bib72] revealed that in India the percentage of ESBL-producing UPEC increased from 45.2 to 59.6% over 5 years (2013--2017). The frequency of ESBL-producing *E. coli* isolates is different in various parts of the world and sometimes even in various hospitals within the country. In addition to resistance to β-lactam antibiotics, ESBL-producing *E. coli* isolates are also resistant to other antimicrobial agents, such as aminoglycosides, tetracycline, and trimethoprim/sulfamethoxazole ([@bib76]). [@bib83] has found that higher number of ESBL-producing UPEC isolates were resistant to aminoglycosides and quinolones when compared to the UPEC strains that not produce ESBL. Carbapenems (imipenem and meropenem) represent the best option for the treatment of UTIs caused by ESBL-producing strains ([@bib42]). Cephalosporins, penicillins, and monobactams should be used with β-lactamase inhibitors ([@bib12]).

Quinolones and fluoroquinolones are extensively used worldwide in the treatment of UTIs and their common use led to increased resistance in UPEC. The mechanism of fluoroquinolone action is based on binding to and impeding the activity of topoisomerase II (DNA gyrase) and topoisomerase IV (parC and parE) ([@bib48]). DNA gyrase is encoded by the *gyrA* and *gyrB* genes ([@bib71]). The resistance of *E. coli* to quinolones frequently results from a mutation in the *gyrA* and *gyrB* genes that catalyze DNA supercoiling. The point mutations in gyrA protein N-terminal sequence (amino acids 67 (Ala-67) to 106 (Gln-106)) strongly correlate with phenotypic resistance to quinolones and fluoroquinolones, and this sequence is named a quinolone resistance-determining region (QRDR) ([@bib34]). Investigation of mutations in codons 83 and 106 of the *gyrA* gene in UPEC isolates in Iran presented the significant relationship between mutations in the *gyrA* gene and quinolone and fluoroquinolone resistance pattern of UPEC isolates ([@bib85]). Other genes responsible for the resistance to quinolones and fluoroquinolones are the *qnr* genes (*qnrA, qnrB*, and *qnrC*), being the most important PMQR (plasmid-mediated quinolone resistance) genes that induce antibiotic resistance by inhibition of binding of quinolones to DNA gyrase and topoisomerases ([@bib83]).

Other mechanisms of *E. coli* resistance to quinolones and fluoroquinolones are related to the presence of efflux pumps and decreased uptake of the antibiotics due to changes in the outer membrane porin proteins ([@bib9]). Abdelhamid and Abozahra (2017) showed that the increased expression of the efflux pump-coding genes *acrA* and *mdfA* was related to the growing resistance to levofloxacin, which confirms that efflux pump systems contribute to fluoroquinolone resistance in urinary *E. coli* isolates.

The mechanism of fosfomycin action is unique because it irreversibly inhibits an early stage of bacterial cell wall biosynthesis, leading to bacterial cell lysis and death ([@bib26]). The active transport proteins used to transport both glucose-6-P and glycerol-3-P are also used by fosfomycin to reach bacterial cytoplasm ([@bib70]). Fosfomycin in the cytoplasm is an analog of phosphoenolpyruvate (PEP) and binds UDP-GlcNAc enolpyruvyl transferase, inactivating this enzyme, which is essential for peptidoglycan biosynthesis. The resistance to fosfomycin is due to three mechanisms that have already been described. One of them is based on decreased uptake of fosfomycin by the bacterial cells due to mutations in the genes that encode the glycerol-3-phosphate transporter or the glucose-6-phosphate transporter ([@bib44]; [@bib93]). The second mechanism is based on point mutations in the binding site of UDP-GlcNAc enolpyruvyl transferase ([@bib47]). The third mechanism of resistance is related to the inactivation of fosfomycin by enzymatic cleavage of the oxirane ring of the antibiotic or by phosphorylation of the phosphonate group. The opening of the oxirane ring may be catalyzed by glutathione transferase (FosA), L-cysteine thiol transferase (Fos B) or fosfomycin-specific epoxide hydrolase (FosX) ([@bib77]).

Nitrofurantoin is recommended for the treatment of uncomplicated cystitis and, currently, the resistance of UPEC to nitrofurantoin is very low. Resistance to nitrofurantoin did not evolve as fast as to other drugs because of this antimicrobial acts at multiple targets in the bacterial cell ([@bib96]). [@bib80] identified mutations conferring resistance to nitrofurantoin and found that the mutation frequency is approximately 10^−7^/cell in *E. coli*. The mutations in the *nsfA* and *nfsB* genes that encode oxygen-insensitive nitroreductases were responsible for nitrofurantoin resistance. It was also found that the growth of bacterial cells in the presence of nitrofurantoin at therapeutic concentrations was greatly reduced in nitrofurantoin-resistant mutants. It may indicate that resistant mutants in the presence of nitrofurantoin were probably unable to establish an infection ([@bib80]).

The resistance of UPEC lineages {#sec12}
===============================

The multilocus sequence-typing (MLST) technique is widely used to study ExPEC lineages. Sequence types (STs) 10, 69, 73, 95, 127, and 131 defined by MLST were isolated as pandemic clones of ExPEC from human infections, including UTIs and bloodstream infections ([@bib89]; [@bib5]; [@bib78]). Globally, these genotypes account for more than 50% of ExPEC infections ([@bib35]; [@bib5]; [@bib45]). The isolates belonging to the lineage ST131 are multidrug-resistant ([@bib11]; [@bib69]). [@bib5] who investigated *E. coli* isolates from bloodstream infections in the United States, found that ST131 was the most common genotype, including 92% of multidrug-resistant isolates. UPEC isolates from patients in the Northwest region of England that belonged to lineage ST131 exhibited higher levels of antibiotic resistance when compared to ST127 isolates that were the most widely susceptible to antibiotics ([@bib35]). The UPEC of ST131 line from a tertiary care hospital in Saudi Arabia was also significantly associated with high levels of antibiotic resistance and 60% of ST131 carried CTX-M-14 and CTX-M-15 ([@bib7]). ST73 was the lineage most frequently identified by [@bib45] among isolates associated with bacteremia in England, and isolates belonging to this lineage were susceptible to most antibiotics. The authors suggested that drug resistance was not a primary determinant for the prevalence of *E. coli* lineages responsible for invasive diseases, and the frequency of *E. coli* lineages is associated with the presence of new lineages outside the hospital. [@bib100] compared the clonal distribution of UPEC in the same community during two periods. The UPEC strains belonging to ST 95, 127, 73, 69, 131, and 10 were responsible for 56% of UTI cases in 1999--2000. In the period 2016--2017, the same STs caused 64% of UTI cases. The study of [@bib100] showed that 46.4% of the isolates resistant to ampicillin in 2016--2017 belonged to four genotypes (ST 95, 127, 73, and 131), while in 1999--2000 they comprised only 21.8%. The increase of resistance to ampicillin was observed only in these genotypes. [@bib100] reported that ST69 included the highest percentage of TMP-SMZ-resistant isolates during two study periods. In 2016--2017, 58% of ciprofloxacin-resistant isolates represented the ST131 lineage. ST69, 127, and 131 comprised 70% of isolates with CTX-M. Among *E. coli* extraintestinal isolates from Iran, the highest rates of the multidrug-resistance phenotype were detected in ST131 (85.7%), and ST69 (41.7%) lineages ([@bib41]). Similarly to the results by [@bib100], the resistance to TMP-SMZ was detected mainly in the ST69 lineage. The widespread occurrence of new multidrug-resistant *E. coli* clonal group ST1193 has recently been demonstrated in the United States ([@bib90]). This clonal group of strains was isolated from younger adults. ST1193 isolates were resistant to fluoroquinolones and often co-resistant to TMP-SXT and tetracycline, but currently, remain susceptible to most β-lactam antibiotics.

Conclusion {#sec13}
==========

The antibiotic therapy is important in the UTI treatment but in recent years it is becoming more challenging due to increasing resistance of UTIs to routinely applied antibiotics. High resistance of UPEC to FQs used as third-line empiric treatment for therapy of uncomplicated cystitis in pyelonephritis or second-line empiric treatment in complicated UTI requires a rational policy of prescription of these drugs. The awareness of the resistance rates of *E. coli* in a given area and the established guidelines for appropriate first-line antibiotic treatment should be critical in the empirical treatment of UTIs, especially for the controlled use of fluoroquinolones.
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